Business
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
LAKE FOREST, Ill., May 08, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026.
About this update from Assertio Holdings, Inc.
[{"type":"text","content":"LAKE FOREST, Ill., May 08, 2026--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026.","length":368,"tagName":"p"},{"type":"text","content":"As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the "Garda Agreement") to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2 million. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. In addition, Assertio will delay the launch of the previously announced tender offer for all outstanding Convertible Senior Notes until May 14, 2026.","length":489,"tagName":"p"},{"type":"text","content":"About Assertio","length":14,"tagName":"p"},{"type":"text","content":"Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market. To learn more about Assertio, visit www.assertiotx.com.","length":297,"tagName":"p"},{"type":"text","content":"Additional Information and Where to Find It","length":43,"tagName":"p"},{"type":"text","content":"The tender offer described in this communication has not yet commenced. This communication is for information purposes only and is neither an offer to buy nor a solicitation of an offer to sell any securities of Assertio Holdings, Inc. ("Assertio"), nor is it a substitute for the tender offer materials that Garda Therapeutics, Inc. ("Garda") and its wholly owned acquisition subsidiary, Audi Merger Sub, Inc. ("Merger Sub"), will file with the Securities and Exchange Commission (the "SEC"). The solicitation and the offer to buy shares of Assertio’s common stock will only be made pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that Garda and Merger Sub intend to file with the SEC. In addition, Assertio will file with the SEC a Solicitation/Recom...